First UK participant enters the largest COVID-19 interventional trial investigating hydroxychloroquine

Image of a healthcare professional in a face mask to show First UK participant enters the largest COVID-19 interventional trial investigating hydroxychloroquine

The first UK participant enters the largest COVID-19 interventional trial in the world investigating hydroxychloroquine and involving 40,000 frontline healthcare workers

The first UK frontline NHS worker will be enrolled as a participant into COPCOV, the largest multi-national interventional clinical study into the prevention of COVID-19 using the investigational medicine, hydroxychloroquine. Enrolment begins today at the Brighton and Sussex University Hospitals and at the John Radcliffe Hospital in Oxford, the first of 20 UK hospitals to participate in this trial.

Over 130 UK frontline healthcare workers have lost their lives from COVID-19 and this study will test if hydroxychloroquine/chloroquine can be used to effectively protect frontline medical staff, allowing them to undertake their vital roles more safely. Accord Healthcare, a UK-based medicines manufacturer, has donated over two million tablets to enable this landmark trial to go ahead.

Dr Anthony Grosso, Vice President and Head of Scientific Affairs, Accord Europe & MENA said: “Based on the known pharmacology of hydroxychloroquine, coupled with the emerging knowledge surrounding SARS-CoV-2 viral replication and COVID-19 pathophysiology, we were very keen to test the effectiveness of this molecule in a preventative, rather than late-stage treatment setting. A large-scale, prospective, randomised, double-blind clinical trial in a high-risk setting is the only way to robustly determine if this medicine can lessen or prevent human infection. Previous studies have not adequately tested this hypothesis; the results of COPCOV are therefore of critical importance to public health.”

“Even though lockdown measures appear to have significantly reduced the current rate of infection in the UK, healthcare workers will continue to be at risk of contracting COVID-19, especially as measures are relaxed. Whilst we wait for an effective and widely available vaccine, the race is on to find a well-tolerated preventative treatment. The results from COPCOV are expected later this year and, if they show that hydroxychloroquine can reduce the chances of catching COVID-19, this would be incredibly reassuring for myself and my frontline colleagues,” said Professor Martin Llewelyn, Brighton and Sussex Medical School and lead COPCOV UK Investigator.

Dr James Burt, Executive Vice President, Accord Europe & MENA said: “I am extremely proud that Accord is leading the way in making this significant investment towards the fight against COVID-19. In addition to providing scientific input, our teams are working around the clock, in challenging times, to manufacture the required hydroxychloroquine and matching-placebo for this vital study. This is a great demonstration of Accord’s mission to help make things better for healthcare professionals on the frontline, patients and society in general.”

Keep up to date with COVID-19 news and features for pharma and healthcare